UBS Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $83
Portfolio Pulse from richadhand@benzinga.com
UBS analyst Eliana Merle has initiated coverage on Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and a price target of $83.
August 28, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS has initiated coverage on Akero Therapeutics with a Buy rating and a price target of $83, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, UBS, a reputable financial institution, has given Akero Therapeutics a Buy rating and set a high price target of $83. This suggests that they expect the stock to perform well, which could encourage investors to buy, potentially driving up the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100